However, gefitinib is generally effective against EGFR-TKI naïve CNS metastasis in EGFR-mutant lung cancer patients, even though only 1% of gefitinib penetrates into the CNS lesions [4, 5, 16, 17]. Here, EGFR is linked to lung carcinoma.